GenisteinSupplementation, CardiacFunction in Postmenopausal-Women with MetabolicSyndrome: Results from Pilot-Strain-Echo Study
A. Bitto,D. Altavilla,F. Squadrito,M. Atteritano,A. Alibrandi,R. Granese,E. Adamo,A. Benedetto,G. Vieste,C. Irace,D. Pancaldo,H. Marini,C. Gregorio,G. Licata,S. Corrao
Abstract:Estrogen favorably influences calcium homeostasis, serum lipid levels, blood pressure control, inflammatory status, and vascular reactivity in women [1,2,3,4,5]. Data from Italian and other European registries indicate that postmenopausal women presenting with traits of metabolic syndrome (MetS), mostly diabetes mellitus (DM) and hyperlipemia, are at high risk of cardiovascular (CV) events [1,6,7]. Moreover, the use of lipid-lowering therapy is strongly influenced by reimbursement criteria revision, and the female gender was identified as a patient-related predictor of low adherence The advantages of estrogen supplementation are preserved in early menopause, failing to maintain cardiovascular protection, thus further therapeutic options continue to be studied Genistein aglycone (hereinafter referred to as genistein) is a soy isoflavone, which has progressively gained clinical consideration for the management of postmenopausal symptoms. Its molecular structure resembles that of 17 β –estradiol and binds the same estrogen-receptors in a dose-dependent manner. Regular supplementation in combination with a Mediterranean-style diet, regular exercise, and medical therapy improve CV risk, endothelial function, and vascular reactivity in MetS women, although, to date, very little data are available concerning the effect of genistein on heart function [12,14,15,16,17,18]. The aim of this study was therefore to investigate whether genistein therapy might influence heart function in postmenopausal patients with MetS. the effect on cardiac function of one-year genistein dietary supplementation in 22 post-menopausal patients with MetS. Participants received 54 mg/day of genistein ( n = 11) or placebo ( n = 11) in combination with a Mediterranean-style diet and regular exercise. Left ventricular (LV) systolic function was assessed as the primary endpoint, according to conventional and strain-echocardiography measurements. Also, left atrial (LA) morphofunctional indices were investigated at baseline and at the final visit. Results were expressed as median with interquartile range (IQ). A significant improvement of LV ejection fraction (20.3 (IQ 12.5) vs. -1.67 (IQ 24.8); p = 0.040)), and LA area fractional change (11.1 (IQ 22.6) vs. 2.8 (9.5); p = 0.034)) were observed in genistein patients compared to the controls, following 12 months of treatment. In addition, body surface area indexed LA systolic volume and peak LA longitudinal strain significantly changed from basal to the end of the study in genistein-treated patients. One-year supplementation with 54 mg/day of pure genistein improved both LV ejection fraction and LA remodeling and function in postmenopausal women with MetS. asymptotic of randomized In group paired measurements signed-rank test
Medicine